Neurosalience logo — Early detection of dementia for decreasing further patient r...

Neurosalience

Early detection of dementia for decreasing further patient related costs and increasing the quality of life of patients.

Founded 2020 United Kingdom London, United Kingdom 2 employees Grant Total: $10.00K Health Care

General Information

Company Name Neurosalience
Founded Year 2020
Location United Kingdom London, United Kingdom +2
Employees 2
Industries Health Care
Funding Stage Grant
Social

Get notified when Neurosalience moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Neurosalience

Neurosalience, founded in 2020 and headquartered in the United Kingdom, is a health care startup with the goal of enabling the early detection of dementia through MRI scans. The company's slogan, "Early detection of dementia for decreasing further patient related costs and increasing the quality of life of patients," encapsulates their mission. Their innovative tool not only identifies dementia at an early stage but also has potential for expansion to CT scans. This technology holds the promise of reducing patient-related expenses while simultaneously enhancing the quality of life for those affected by dementia. Neurosalience's progress has garnered the attention of investors, with their most recent €10.00K grant investment coming from Prototron on 29 January 2021.

Taxonomy: Medical Imaging, Dementia Detection, Diagnostic Tools, MRI Analysis, CT Scan Analysis, Healthcare Costs Reduction, Patient Quality of Life, Neurological Health, Medical Device Development

Services & Products

Early detection tool for dementia using structural MRI and CT data

Target Customers

Hospitals MedTech companies pharmaceutical companies

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Grant €10.00K 1 Prototron 29 Jan 2021

Neurosalience Alternatives & Competitors

Neurosalience vs

Enhancing MRI accuracy by minimizing motion artifacts, ensuring superior scan quality with every use...

Series B
Health Care, Medical Devices
Neurosalience vs
VUNO Inc.
VUNO Inc. Korea South

View the Invisible, Know the Unknown.

98 employees
Neurosalience vs
Altris AI
Altris AI United States

AI Decision Support for OCT Analysis that elevates Ophthalmology, Research, and Optometry.

Seed
33 employees
AI, Biotechnology

FAQ About Neurosalience

Early detection of dementia for decreasing further patient related costs and increasing the quality of life of patients.
Neurosalience was founded in 2020.
Neurosalience is headquartered in London, United Kingdom.
Neurosalience operates in the following industries: Health Care.
Neurosalience has approximately 2 employees.
Neurosalience has completed 1 funding round, raising a total of $10.00K. The latest funding stage is Grant.
Neurosalience offers: Early detection tool for dementia using structural MRI and CT data.
Top alternatives and competitors to Neurosalience include Kineticor, VUNO Inc., Altris AI, 3D-Shaper Medical, Better Medicine. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Neurosalience and Kineticor are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Neurosalience and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

One analytics cookie (Google Analytics). Cookie Policy